Marker Therapeutics, Inc.

Monthly Archives: December 2015

TapImmune Presents New Data at San Antonio Breast Cancer Symposium Showing Robust Generation of T-Cell Immunity

JACKSONVILLE, Florida, December 10, 2015 Vaccination with TPIV 100 boosts T-cell immunity to HER2 in HER2+ Breast Cancer Patients Provides catalyst to start Phase II studies TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer &
Read More

TapImmune to Present New Data at San Antonio Breast Cancer Symposium on December 10, 2015

TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, today announced its Chairman and CEO, Dr.
Read More